Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NKG2D CAR-NK for Platinum-Resistant Ovarian Cancer
NCT05776355Phase 1Unknown
- Sponsor
- Hangzhou Cheetah Cell Therapeutics Co. Ltd.
- Start
- Mar 2023
- Primary completion
- Apr 2024
- Modality
- Gene Editing, Gene Silencing, Lymphokine-Activated Killer Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of NKG2D CAR-NK in ovarian cancer, sponsored by Hangzhou Cheetah Cell Therapeutics Co. Ltd. Primary endpoints: Dose Limiting Toxicity at 28 days and Maximum Tolerated Dose at 28 days. Status: unknown.
02
Drugs
NKG2D CAR-NK
03
Conditions
ovarian cancer
Beyond the preview
Go deeper on NCT05776355.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05776355.